PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tobramycin - Cystic fibrosis
PAD Profile : Tobramycin - Cystic fibrosis
Keywords :
NICE, antibiotic, antibacterial, aminoglycoside
Brand Names Include :
Tobi, Bramitob, Vantobra
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Aztreonam
- Colistimethate sodium
- Dornase alfa
- Ivacaftor
- Levofloxacin
- Amikacin
- Ciprofloxacin
- Lumacaftor/ivacaftor
- Mannitol
- Tezacaftor/ivacaftor
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
01 April 2013
Not Set
FOR NEW PATIENTS ONLY. Prescribing of Tobramycin will be considered RED on the Prescribing Advisory database. Historically amber for CF patients via nebulisation / inhalation (Not Tobi-Podhaler which has historically been RED). Funding now rests with NHS England for this treatment
FOR EXISTING PATIENTS: GPs should continue to prescribe these treatments. NHS England are looking to repatriate these patients in the future. The Medicines Management Team will be in contact with prescribers when they have more information
Associated BNF Codes
05. Infections
05.01.04. Aminoglycosides